iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares of Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $101.84, for a total transaction of $509,200.00. Following the completion of the sale, the chief executive officer owned 2,267,500 shares in the company, valued at $230,922,200. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

iRadimed Stock Performance

Shares of NASDAQ:IRMD opened at $103.22 on Thursday. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of 62.56 and a beta of 1.09. iRadimed Corporation has a 1-year low of $47.48 and a 1-year high of $104.04. The company has a 50 day moving average price of $95.43 and a 200 day moving average price of $79.24.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. The company had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, sell-side analysts expect that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Announces Dividend

The business also recently declared a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were paid a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is currently 41.21%.

Analyst Ratings Changes

IRMD has been the subject of several recent analyst reports. Zacks Research upgraded shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Lake Street Capital reiterated a “buy” rating and set a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Finally, Roth Mkm set a $90.00 target price on iRadimed in a research report on Friday, October 31st. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.00.

Institutional Investors Weigh In On iRadimed

A number of institutional investors have recently modified their holdings of IRMD. CWM LLC raised its holdings in shares of iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 211 shares in the last quarter. Quarry LP acquired a new position in iRadimed in the 3rd quarter worth about $40,000. Tower Research Capital LLC TRC increased its position in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of iRadimed during the 3rd quarter worth about $47,000. Finally, Spire Wealth Management acquired a new stake in shares of iRadimed during the 2nd quarter valued at about $60,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.